

May 25, 2019

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,


This is to inform you that the meeting of the Board of Directors of the Company scheduled on Wednesday, 29 May, 2019, will consider, apart from audited financial result and declaration of dividend, also consider the proposal to enable raising of funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency(ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt.

Please treat this as the intimation required under Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

The above is for your information.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)